Document 0394
 DOCN  M9610394
 TI    Quantitative relationship of circulating p24 antigen with human
       immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected
       subjects receiving antiretroviral therapy. The RV43 Study Group.
 DT    9601
 AU    Brown AE; Vahey MT; Zhou SY; Chung RC; Ruiz NM; Hofheinz D; Lane JR;
       Mayers DL; Walter Reed Army Institute of Research, Henry M. Jackson;
       Foundation for the Advancement of Military Research, Rockville,; MD
       20850, USA.
 SO    J Infect Dis. 1995 Oct;172(4):1091-5. Unique Identifier : AIDSLINE
       MED/96029381
 AB    To better understand the biologic meaning and potential clinical utility
       of p24 antigen measurements in human immunodeficiency virus (HIV)
       infection, p24 antigen and antibody and HIV RNA were quantitated in
       parallel. Specimens (n = 311) were analyzed from 74 participants in a
       zidovudine treatment study. Parallel antigen and RNA measurements
       revealed the frequent occurrence of two types of discordant results.
       First, p24 antigen was often not detected in samples with high antibody
       levels even when > 10(6) RNA copies/mL were present. Second, in
       specimens in which p24 antigen was detected, the concentration was
       greater than expected on the basis of HIV RNA values. These results
       suggest that optimal use of serum p24 antigen values will require
       consideration of both specific antibody levels and non-virion associated
       antigen.
 DE    Adult  Base Sequence  Blotting, Western  CD4 Lymphocyte Count  Female
       Human  HIV Antibodies/*BLOOD  HIV Core Protein p24/*BLOOD  HIV
       Infections/*DRUG THERAPY/IMMUNOLOGY  Male  Molecular Sequence Data  RNA,
       Viral/*BLOOD  Statistics  Support, U.S. Gov't, Non-P.H.S.
       Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).